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Abstract
DNA replication produces tangled, or catenated, chromatids, that must be decatenated prior to mitosis or catastrophic
genomic damage will occur. Topoisomerase IIa (Topo IIa) is the primary decatenating enzyme. Cells monitor catenation
status and activate decatenation checkpoints when decatenation is incomplete, which occurs when Topo IIa is inhibited by
chemotherapy agents such as the anthracyclines and epididophyllotoxins. We recently demonstrated that the DNA repair
component Metnase (also called SETMAR) enhances Topo IIa-mediated decatenation, and hypothesized that Metnase could
mediate resistance to Topo IIa inhibitors. Here we show that Metnase interacts with Topo IIa in breast cancer cells, and that
reducing Metnase expression significantly increases metaphase decatenation checkpoint arrest. Repression of Metnase
sensitizes breast cancer cells to Topo IIa inhibitors, and directly blocks the inhibitory effect of the anthracycline adriamycin
on Topo IIa-mediated decatenation in vitro. Thus, Metnase may mediate resistance to Topo IIa inhibitors, and could be a
biomarker for clinical sensitivity to anthracyclines. Metnase could also become an important target for combination
chemotherapy with current Topo IIa inhibitors, specifically in anthracycline-resistant breast cancer.
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Introduction
Topo IIa inhibitors such as anthracyclines or epididophyllotox-
ins are important agents in the treatment of human malignancy
[1–3]. These agents cause DNA damage by two mechanisms,
locking Topo IIa in a cleavage complex producing DNA double-
strand breaks (DSBs), and inhibiting chromatid decatenation [3].
While the former mechanism is well understood, far less is known
about the latter, yet it can be just as catastrophic to the cell. Failure
of decatenation results in DSBs at anaphase, and to prevent this
cells probably monitor decatenation at two positions in the cell
cycle, at the G2/M boundary and at the metaphase to anaphase
transition [4–10]. These decatentation checkpoints are activated
independently of the G2/M DNA damage-dependent checkpoint
[3,9,11,12]. Interestingly, lung and bladder cancers proceed
through the decatenation checkpoints even in the presence of
high levels of Topo IIa inhibitors, and this was thought to be
secondary to a failure of the cell cycle arrest machinery [13,14].
We recently isolated and characterized a human protein with
SET and transposase domains called Metnase [15]. Metnase
promotes non-homologous end joining DNA repair [15–18],
enhances plasmid and viral DNA integration [18], and cleaves but
does not degrade supercoiled plasmid DNA [19]. We recently
showed that Metnase interacts with Topo IIa and enhances its
function in chromosomal decatenation [19]. Therefore, we
hypothesized that Metnase may mediate the resistance of
malignant cells to Topo IIa inhibitors, and chose to test this in
breast cancer cells because anthracyclines are among the most
important agents in the treatment of this disease [1,20–22]. We
report here that Metnase interacts with Topo IIa in breast cancer
cells, promotes progression through metaphase in breast cancer
cells treated with a Topo IIa inhibitor, sensitizes breast cancer cells
to the anthracycline adriamycin and the epididophyllotoxin VP-
16, and directly blocks Topo IIa inhibition by adriamycin in vitro.
These data indicate that Metnase levels may be one reason why
some breast cancer cells treated with Topo IIa inhibitors can
progress through mitosis without catastrophe resulting in drug
resistance.
Results and Discussion
Previously, we showed that Metnase expression directly
correlates with Topo IIa mediated decatenation in Human
Embryonic Kidney cells. To determine if this finding would
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expression in four breast cell lines. MCF-10A is a cell line isolated
from a benign hyperplastic breast lesion, T-47D from an
infiltrating ductal carcinoma, HCC1937 from a primary ductal
carcinoma, and MDA-MB-231 from a metastatic adenocarcino-
ma. As shown in Figure 1A, all of the cell lines express both
Metnase and Topo IIa, though the HCC1937 have significantly
reduced Topo IIa levels. Interestingly, MDA-MB-231 cells are the
only cell line shown here derived from metastatic breast tissue.
They have both an elevated Topo IIa level and significant
Metnase expression. Because of this, we chose these cells to
determine if Metnase and Topo IIa interact in breast cancer. In
Figure 1B, we show that Metnase does co-immunoprecipitate (co-
IP) with Topo IIa and that Topo IIa co-IPs with Metnase.
Together, this provides evidence that Metnase could play a role in
the pathogenesis and resistance of metastatic breast cancer to
Topo IIa inhibiting therapies.
Since Metnase enhances Topo IIa-mediated decatenation, and
enhances resistance to ICRF-193 and VP-16 in non-malignant
human cells [19], we hypothesized that Metnase might also promote
resistance to the anthracyclines and epididophyllotoxins in MDA-
MB-231 cells. We first investigated whether reducing Metnase would
affect ICRF-193-mediated metaphase arrest. MDA-MB-231 cells
were treated with ICRF-193, which inhibits Topo IIa after DNA
religation, and therefore does not induce DSBs but does inhibit
decatenation, allowing for discrimination between DNA damage and
metaphase arrest [3]. The increase in cells arrested at metaphase in
the presence of ICRF-193 compared to vehicle controls provides a
measure of cells arrested due to failure of decatenation. Using a-
tubulin immunofluorescence microscopy, we determined the fraction
of cells in metaphase after exposure to ICRF-193. Cells with reduced
Metnase expression (Fig. 2A) showed a significantly higher
percentage of metaphase arrested cells when treated with ICRF-
193 and cytospun onto slides to retain all cells(Fig. 2C).After 18 hour
treatments with 2 or 10 mM ICRF-193, or 4 hours with 10 mM
ICRF-193, cells with reduced Metnase showed 4.9-fold (p-
value=0.0016), 2.2-fold (p-value=0.027), and 2.6-fold (p-val-
ue=0.00015) increased metaphase arrest, respectively, as compared
to vector control and evaluated by student’s t-test (Fig. 2B). This result
suggests that Metnase promotes decatenation in ICRF-193-treated
MDA-MB-231 cells, allowing them to proceed through metaphase
even in the presence of this Topo IIa specific inhibitor.
Prior studies revealed that bladder and lung cancer cells
progress through the decatenation checkpoints when Topo IIa is
inhibited by high concentrations of ICRF-193 [13,14]. The
conclusion from those studies was that these cancer cells failed to
arrest because they had inactivated the decatenation checkpoints.
While the ability to progress through mitosis even when Topo IIa
is inhibited may be a general feature of malignancy, it may be due
to the presence of Metnase alone, or Metnase in combination with
checkpoint inactivation. Thus, the decatenation checkpoint may
be intact in these malignant cells, but Metnase promotes continued
Topo IIa function despite the presence of inhibitors, and the
decatenation checkpoint is not activated.
The Topo IIa inhibitor ICRF-193 does not induce significant
DNA damage, and therefore is not relevant in the clinical therapy
of breast cancer. To determine whether altering Metnase levels
would affect resistance to clinically relevant Topo IIa inhibitors,
such as VP-16 and adriamycin [1,2], we determined the
cytotoxicity of these agents in MDA-MB-231 cell lines that stably
under-expressed Metnase using colony formation assays. De-
creased Metnase expression increased sensitivity 7.5-fold to VP-16,
and 3.5-fold to adriamycin (Fig. 3A and B). Together, these results
indicate that Metnase expression levels directly correlate with cell
survival after exposure to these clinically relevant Topo IIa
inhibitors. Adriamycin is an important agent in both adjuvant
therapy and in the treatment of metastatic breast adenocarcinoma
[1], so this finding is of relevance for current clinical regimens. It
raises the possibility that treatment efficacy could be improved if
the drug was used in combination with a future Metnase inhibitor,
or if Metnase levels could be measured and possibly account for
variance in responsiveness to adriamycin based chemotherapeutic
regimens. Altogether, these results provide further support for the
hypothesis that Metnase plays a key role in Topo IIa function.
Figure 1. Topo IIa and Metnase interact in breast cancer cells. (A)
MCF 10A, MDA-MB-231, T-47D, and HCC1937 were analyzed by Western
blot for expression of Topo IIa and Metnase protein expression. Actin is
shown as a loading control. (B) Metnase and Topo IIa were immunopre-
cipitated from MDA-MB-231 cells and analyzed by Western blot.
doi:10.1371/journal.pone.0005323.g001
Figure 2. Metnase shRNA expression induces metaphase arrest
in MDA-MB-231 cells. (A) Metnase expression was reduced by shRNA
expression in MDA-MB-231 cells and analyzed by RT-PCR of mRNA and
Western blot of protein, with 18S RNA and b-actin levels as loading
controls. (B) Quantification of metaphase arrest after treatment with 2
or 10 mM ICRF-193 for 18 hrs. The percentages of metaphase cells in
DMSO control cultures were subtracted from ICRF-193 treated cultures.
Values are averages (+SEM) for 10–15 determinations; single asterisk
indicates P=0.022 and double asterisk indicates P=0.0002 (t tests). (C)
Representative images of control (shGFP) and Metnase knockdown cells
expressing treated with ICRF-193 and stained with a-tubulin (green)
and DAPI; arrows indicate metaphase cells.
doi:10.1371/journal.pone.0005323.g002
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mediate sensitivity to Topo IIa inhibitors, we investigated whether
Metnase levels affected the cellular apoptotic response to
adriamycin. We exposed MDA-MB-231 cells to adriamycin for
24 hrs and then evaluated annexin-V/FITC fluorescence by flow
cytometry. We found that shRNA down-regulation of Metnase
levels markedly sensitized these breast cancer cells to adriamycin-
induced apoptosis (Fig. 3C). Compared to vector controls, cells
with reduced Metnase levels showed a 17-fold higher frequency of
apoptosis after adriamycin exposure. This finding suggests that
Metnase suppresses adriamycin-induced apoptosis, contributing to
the increased resistance of breast cancer cells to this drug.
To define the underlying mechanism of Metnase-dependent
adriamycin resistance, we examined the effect of Metnase on
adriamycin inhibition of Topo IIa-mediated decatention using a
kinetoplast DNA (kDNA) in vitro decatenation assay (Fig. 4). Topo
IIa decatenates kDNA (lanes 2–4) and adriamycin completely
inhibits this activity (lane 5). As shown previously [19], purified
Metnase does not decatenate kDNA on its own (lane 6), but
enhances Topo IIa-dependent kDNA decatenation by 4-fold (lane
8). Importantly, when Metnase is present, it overcomes the
inhibition of Topo IIa by adriamycin, and this is true whether
Metnase is added to the reaction before or after adriamycin (lanes
9–10). Note also that in the presence of Metnase, there is a greater
level of decatentation in the presence of adriamycin than with
Topo IIa alone in the absence of adriamycin (compare lanes 9 and
10 with lane 4).
Metnase is a known component of the DSB repair pathway, and
may enhance resistance to Topo IIa inhibitors by two mecha-
nisms, enhancing DSB repair [15,16] or enhancing Topo IIa
function [19]. The data presented here suggest that the ability of
Metnase to interact with Topo IIa, and enhance Topo IIa-
Figure 3. Metnase levels predict breast cancer cell sensitivity to Topo IIa inhibitors. Cells stably transfected with vector control, or
Metnase shRNA were treated with VP-16 (A) or adriamycin (B) and colony survival was measured as described. Values are averages 6SEM for three
determinations. (C) Cells transfected with control (shGFP) or Metnase shRNA were treated with 1 mM adriamycin for 24 hrs and apoptosis (annexin-V)
and cell death (propidium iodide) were analyzed by FACS. Values are averages (+SEM) for three determinations.
doi:10.1371/journal.pone.0005323.g003
Figure 4. Metnase blocks the inhibitory effect of adriamycin on Topo IIa decatenation of kDNA. kDNA was incubated with varying
amounts of Topo IIa (lanes 1–4), Topo IIa and adriamycin (lane 5), Metnase alone (lane 6), Metnase and adriamycin (lane 7), or Topo IIa and Metnase
(lane 8). In lanes 9 and 10, kDNA was incubated with Topo IIa, Metnase and adriamycin with different orders of addition as indicated below.
doi:10.1371/journal.pone.0005323.g004
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important as its ability to promote DSB repair in surviving
exposure to clinical Topo IIa inhibitors. It is possible that Metnase
could bind Topo IIa and physically block binding by adriamycin.
In this model, Metnase would be bound to Topo IIa on DNA, and
prevent adriamycin from stabilizing the Topo IIa/DNA cleavage
complex, allowing Topo IIa to complete re-ligation. Alternatively,
Metnase may function as a co-factor or chaperone to increase
Topo IIa reaction kinetics. Here Metnase would bind transiently
to Topo IIa and increase its reaction rate regardless of adriamycin
binding. The mechanism may also be a functional combination of
these two mechanisms where Metnase increases Topo IIa kinetics
while also blocking further binding of the drug.
Our interpretation of these data is that Metnase increases the
intrinsic function of Topo IIa via one of the above mentioned
molecular mechanisms, and that this will result in fewer DSBs, not
necessarily from enhanced DNA repair, but from Topo IIa
directly resisting adriamycin inhibition and thus inhibiting the
production of DSBs. This model is supported by our findings that
Metnase significantly blocks breast cancer cell metaphase arrest
induced by ICRF-193, and that cellular resistance to Topo IIa
inhibitors is directly proportional to the Metnase expression level.
Our data reveal a novel mechanism for adriamycin resistance in
breast cancer cells that may have important clinical implications.
Metnase may be a critical biomarker for predicting tumor response
to Topo IIa inhibitors. By monitoring Metnase levels, treatments
with Topo IIa inhibitors may be tailored to improve efficacy. In
addition, since reduced Metnase levels increase sensitivity to clinical
Topo IIa inhibitors, inhibiting Metnase with a small molecule could
improve response in combination therapies. Metnase inhibition
may be especially important in a recurrent breast tumor that was
previously exposed to Topo IIa inhibitors, since resistance to these
agents may be due to upregulation of Metnase and/or Topo IIa.I n
summary, Metnase mediates the ability of Topo IIa to resist
clinically relevant inhibitors, and may itself prove clinically useful in
the treatment of breast cancer.
Materials and Methods
Cell culture, manipulating Metnase levels and co-
immunoprecipitation
MDA-MB-231, T47, and HCC1937 breast cancer cell lines
were cultured in Dulbecco’s modified medium fully supplemented
with 1% antimycotic/antibiotic (Cellgro, Mannasas, VA), and
10% Fetal Bovine Serum (Atlanta Biologicals, Lawrenceville, VA).
The MCF10-A cell line was cultured in DMEM/F12 (Invitrogen,
Carlsbad, CA) fully supplemented with 5% horse serum (Invitro-
gen, Carlsbad, CA), 20 ng/mL EGF (Invitrogen, Carlsbad, CA),
10 mg/L Insulin (Sigma, St. Louis, MO), 100 nM Hydrocortisone
(Invitrogen, Carlsbad, CA), and 100 ng/mL Cholera toxin
(Sigma, St. Louis, MO). MDA-MB-231 cells (ATCC) were stably
transfected with pRS expressing shGFP control or shRNAs
targeted to Metnase’s nuclease domain in nucleotides 1198–
1226, 1270–1298, and 1800–1828 (Origene, Rockville, MD).
Metnase levels were assessed using RT-PCR and Western blotting
[15]. Co-immunoprecipitation of Metnase and Topo IIa using
anti-Topo IIa (Topogen, Port Orange, FL) was performed in the
presence of 1.0 U/mL DNase I.
Analysis of metaphase decatenation arrest
ICRF-193 (MP Biomedicals, Solon, OH) reversibly inhibits
Topo IIa without inducing DNA DSBs, thereby allowing
assessment of the decatenation checkpoints without activating
the DNA damage checkpoints [7,23]. ICRF-193 was dissolved in
DMSO and further diluted in growth medium. Unsynchronized
cells were treated with 2 or 10 mM ICRF-193, or an equivalent
volume of DMSO (vehicle control) for 4 or 18 hours as labeled,
harvested, cytospun, fixed with ice cold methanol, and stained
with anti-tubulin antibody conjugated to FITC (Abcam, Cam-
bridge, MA) for 2 hrs at room temperature and 49-6-diamidino-2-
phenylindole (DAPI, Vectashield). Interphase and metaphase cells
were counted by immunofluorescence microscopy (Nikon TE2000
inverted microscope equipped with filter sets specific to FITC and
DAPI). The fractional increase in ICRF-193 metaphase-arrested
cells over vehicle controls was due to failure to traverse the
metaphase decatenation checkpoint [3,5,8–10]. Data were col-
lected from $1500 cells in duplicate experiments.
Cytotoxicity of topoisomerase II inhibitors and analysis of
apoptosis
Cells expressing various levels of Metnase were treated with VP-
16 for 8 hr or adriamycin for 4 hr in growth medium, washed
twice, fresh growth medium replaced, and incubated at 37uC with
5% CO2 for 10–14 days. Plating efficiencies were calculated by
plating untreated cells in a similar manner. Colonies were stained
with 1% methylene blue (Sigma, St. Louis, MO) and counted and
percent survival was calculated after normalization to plating
efficiency of untreated control cells. Apoptosis was analyzed by
measuring annexin-V expression in cells treated with 1.0 mM
adriamycin for 24 hr using the Annexin V-FITC Apoptosis
Detection Kit I (BD Pharmingen, NJ).
Kinetoplast DNA decatention
Purified recombinant Topo IIa (GE Healthcare, Piscataway,
NJ) and catenated kinetoplast DNA (kDNA, Topogen, Port
Orange, FL) were used according to the manufacturers’
instructions. Recombinant Metnase was purified as described
[24]. Adriamycin was added to specific reactions at a final
concentration of 20 mM and kDNA decatenation was visualized
by agarose gel electrophoresis.
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